Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029. The company remains on track to deliver core operating ...

Basel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company’s leadership in improving access to medicines around ...

Explore opportunities with Novartis below.

Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...

Montreal, November 15, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular ...